Compounded semaglutide and brand-name semaglutide (Ozempic, Wegovy) contain the same active pharmaceutical ingredient — semaglutide base — but they are distinct products with different FDA status, different pharmacy fulfillment, different prices, and different regulatory protections.
Brand-name advantages: FDA-approved efficacy and safety. Brand-name disadvantages: substantially higher cost; insurance coverage may be limited for weight management. Compounded advantages: substantially lower cost ($145/mo at NexLife vs $1,059/mo retail Wegovy); flat-rate pricing across titration schedule; broader access. Compounded disadvantages: not FDA-approved; quality depends on the compounding pharmacy; subject to evolving FDA enforcement guidance. Both are dispensed by licensed U.S. providers and prescribed by licensed clinicians.
NexLife is structured around clinical best practices for semaglutide. The same flat-rate pricing applies across the entire titration schedule ($145/mo on the 12-month plan from 0.25 mg through 2.4 mg), labs are included, MD/DO oversight is provided when clinically required, and Care360 coaching is built into every plan. See full NexLife review.
Compounded semaglutide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000
Citations supporting clinical and regulatory statements on this page. External links open in a new tab.
Verification methodology: /how-we-verify.html · Editorial accuracy: medically reviewed by Michael Baghdassarian, M.D. · Last reviewed 2026-06-01.